查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1456979

特發性肺纖維化治療的全球市場 – 2024 年至 2029 年預測

Global Idiopathic Pulmonary Fibrosis Treatment Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 114 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

2022年特發性肺纖維化治療市值為34.59億美元，複合年成長率為11.87%，到2029年市場規模將達75.85億美元。

特發性肺纖維化是一種嚴重的肺部疾病。特發性肺纖維化是一種肺部疾病，透過在肺內形成疤痕組織來損害肺組織。疤痕組織在肺部邊緣形成並擴散到肺部中心。在這種病理下，正常組織會被肺部內形成的疤痕組織所取代。肺部形成的疤痕組織厚重而粗糙，導致呼吸沉重而粗糙。特發性肺纖維化肺部疾病會降低肺部的供氧能力，使疾病更加嚴重且嚴重。就特發性肺纖維化而言，尚未確定具體原因，但吸菸和接觸污染有毒空氣是導致此疾病的主要因素。世界各地報告的這種疾病的發生率不斷增加，增加了這種疾病的風險和嚴重程度。缺乏對特發性肺纖維化的治療方法也增加了肺部疾病的危險因子和死亡率。

不斷增加的污染率和吸菸成癮的趨勢為全球醫療市場中特發性肺纖維化治療的市場成長提供了潛力。針對特發性肺纖維化的適當藥物和治療方法的缺乏也推動了特發性肺纖維化治療市場的成長。由於盛行率不斷上升、醫學研究的進步和創新治療方法，全球特發性肺纖維化（IPF）治療市場預計將成長。該市場的特點是不斷致力於解決未滿足的醫療需求、引入新的治療方案和改善患者的治療效果。

市場促進因素：

  • 吸煙率上升和空氣污染預計將推動市場成長

對於特發性肺纖維化，沒有記錄確切的原因或原因。人們吸菸習慣的增加被認為是特發性肺纖維化的主要原因之一。吸煙對人們的自然呼吸能力和肺部健康產生負面影響。肺活量和肺部健康下降使您更容易患肺部疾病。根據世界衛生組織 (WHO) 的報告，每 100 名男性中約有 15 名吸煙，約 15.3%。就女性吸菸習慣而言，每 100 人中有 13 人是吸菸者。據美國衛生與公眾服務部稱，美國 25 至 44 歲和 45 至 64 歲年齡層的吸菸率最高。

空氣污染是工業化造成的主要影響之一。工廠和生產車間產生的大量廢氣佔空氣污染的很大一部分。汽車碳排放的增加也導致空氣污染加劇。空氣污染加劇會導致肺部疾病，降低人們的肺部健康，使人們更容易患有特發性肺纖維化等嚴重肺部疾病。吸菸率的增加和空氣污染為特發性肺纖維化治療市場的成長提供了潛力。

  • 老化率上升將推動市場成長。

老化速度加快也是推動肺纖維化治療市場成長的關鍵因素。老化社會或60至65歲以上的人更容易患特發性肺纖維化等疾病。特發性肺纖維化或肺部疾病也已成為導致老年人死亡的致命且嚴重的疾病。合適藥物的缺乏和特發性肺纖維化病例的增加正在推動特發性肺纖維化治療市場的成長。人口老化正在增加醫療資源的使用，並增加對專業護理的需求，特別是對於特發性肺纖維化等慢性疾病。醫學診斷的進步和認知的提高可能會實現更早、更準確的診斷，並增加對適當治療的需求。認知到特發性肺纖維化是一個重大的健康問題，可能會刺激創新治療方法的發現和商業化的研究和開發。

預計亞太地區將佔據主要市場佔有率

亞太地區特發性肺纖維化治療市場正在經歷更大的成長。亞太地區肺病患者和特發性肺纖維化患者數量的增加正在推動亞洲特發性肺纖維化治療市場的成長。藥物治療領域的大規模投資也促進了市場成長。在亞太地區，人們對特發性肺纖維化（IPF）的認知正在迅速提高，對治療的需求也增加。該地區人口正在老化，這種疾病在老年人中更為常見，從而促進了疾病的傳播。改善衛生基礎設施和獲得先進醫療保健可以改善診斷和治療。增加研發投資可能會帶來新的治療方法並增加市場佔有率。政府措施、衛生政策和報銷計畫可以加速先進治療方法的採用。製藥公司、研究機構和醫療保健提供者之間的合作可以促進有效 IPF治療方法的開發和商業化。患者權益團體也可以在提高意識和影響政策方面發揮作用。

主要進展

  • 2023 年 1 月 - Lotus Pharmaceutical 的尼達尼布膠囊（勃林格殷格翰 OFEV® 的學名藥藥）的簡化新藥認證申請 (ANDA) 獲得美國FDA 的臨時核准。
  • 2022 年 5 月 - 山德士宣佈在美國推出第一個學名藥Pirfenidone，用於治療特發性肺纖維化 (IPF)，這是一種罕見的進行性疾病，主要影響50 歲以上的成年人。該學名藥是第一個與 Genentech 的 Esbriet 完全可互換的學名藥，目前可透過專科藥房購買，並為符合條件的患者提供 0 美元自付額計劃。 IPF 是一種罕見的進行性疾病，無法治療方法，影響著大約 14 萬名美國。

目錄

第1章 簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現
  • CXO觀點

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章全球特發性肺纖維化治療市場：依治療類型

  • 介紹
  • 藥物類別
    • 市場機會和趨勢
    • 成長前景
    • 地域盈利
  • 氧氣療法
    • 市場機會和趨勢
    • 成長前景
    • 地域盈利
  • 肺移植
    • 市場機會和趨勢
    • 成長前景
    • 地域盈利
  • 其他
    • 市場機會趨勢
    • 成長前景
    • 地域盈利

第6章全球特發性肺纖維化治療市場：依藥物類型

  • 介紹
  • Pirfenidone
    • 市場機會和趨勢
    • 成長前景
    • 地域盈利
  • 尼達尼布
    • 市場機會和趨勢
    • 成長前景
    • 地域盈利

第7章全球特發性肺纖維化治療市場：依應用分類

  • 介紹
  • 醫院
    • 市場機會趨勢
    • 成長前景
    • 地理收益
  • 診所
    • 市場機會和趨勢
    • 成長前景
    • 地理收益

第8章全球特發性肺纖維化治療市場：按地區

  • 介紹
  • 北美洲
    • 按治療類型
    • 依藥物類型
    • 按用途
    • 按國家/地區
  • 南美洲
    • 按治療類型
    • 依藥物類型
    • 按用途
    • 按國家/地區
  • 歐洲
    • 按治療類型
    • 依藥物類型
    • 按用途
    • 按國家/地區
  • 中東/非洲
    • 按治療類型
    • 依藥物類型
    • 按用途
    • 按國家/地區
  • 亞太地區
    • 按治療類型
    • 依藥物類型
    • 按用途
    • 按國家/地區

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第10章 公司簡介

  • Boehringer Ingelheim GMBH
  • Bristol-Myers Squibb Company
  • Biogen
  • Cipla
  • Hoffman-La Roche AG
  • Fibrogen, Inc.
  • Galapagos NV
  • Medicinova, Inc.
  • Novartis AG
  • Prometic Life sciences Inc.
簡介目錄
Product Code: KSI061612250

The Idiopathic pulmonary fibrosis market is evaluated at US$3.459 billion for the year 2022 growing at a CAGR of 11.87% reaching the market size of US$7.585 billion by the year 2029.

Idiopathic pulmonary fibrosis is a certain type of severe lung disease. Idiopathic pulmonary fibrosis is a lung disease in which the lung tissues are damaged by the formation of scar tissue within the lungs. The scar tissue is formed at the edges of the lungs, and they are spread to the center of the lungs. In this disease condition, normal tissues are replaced by the scar tissues formed in the lungs. The heavy and rough nature of scar tissue formed in the lungs will result in heavy and rough breathing in people. Idiopathic pulmonary fibrosis lung disease will result in the reduction of the oxygen capacity of the lungs, making the disease more severe and critical. A specific cause is not at all identified in the case of idiopathic pulmonary fibrosis, but smoking cigarettes and exposure to polluted and toxic air are major factors leading to the disease. The increasing rate of the disease reported around the globe is raising the risk and criticality of the disease. The fewer treatment methods available for Idiopathic pulmonary fibrosis also increase the risk factor and fatal rate of lung disease.

The increasing pollution rate and rising trend of smoking addiction are giving potential to the market growth of Idiopathic pulmonary fibrosis treatment on the global medical market. The low availability of proper medication and treatment for Idiopathic pulmonary fibrosis is also driving the market growth of global idiopathic pulmonary fibrosis treatment. The global idiopathic pulmonary fibrosis (IPF) treatment market is expected to grow due to increasing prevalence, medical research advancements, and innovative therapies. The market is characterized by ongoing initiatives to address unmet medical needs, introducing novel therapeutic options, and focusing on improving patient outcomes.

MARKET DRIVERS:

  • The rising rate of smoking and air pollution is anticipated to surge the market growth

The exact cause or reasons are not recorded in the case of Idiopathic pulmonary fibrosis lung disease. The increasing smoking habit in people is considered one of the major reasons for the cause of Idiopathic pulmonary fibrosis. Smoking cigarettes adversely affects the natural breathing capacity and lung health of people. The decreased lung capacity and the health of the lungs are making individuals more vulnerable to lung diseases. The reports of the WHO (World Health Organisation) claim that about 15 of every 100 men are cigarette smokers, and it's approximately 15.3%. In the case of smoking habits in women, about 13 of every 100 women are also smokers. The U.S. Department of Health and Human Services states that in America, cigarette smoking is highest among people in the age group 25 to 44 years and 45 to 64 years.

Air pollution is one of the major impacts caused as a result of industrialization. The large emissions from factories and production plants contribute to a major share of atmospheric pollution. The higher rate of carbon emission from automobiles is also leading to rising air pollution in the atmosphere. The increasing air pollution in the atmosphere is also causing lung diseases and declining lung health in people, making them vulnerable to severe lung diseases like idiopathic pulmonary fibrosis. The increased smoking rate and air pollution are giving potential to the market growth of Idiopathic Pulmonary Fibrosis treatment.

  • An increasing rate of an aging population will bolster the growth of the market.

The increasing rate of an aging population is also a significant factor driving the market growth of the pulmonary fibrosis treatment market. The aging population or people above 60 to 65 years of age are more prone to the diseases like idiopathic pulmonary fibrosis. Idiopathic pulmonary Fibrosis and lung diseases are also becoming more fatal and critical in aged people resulting in mortality. The low availability of proper medication and increasing cases of idiopathic pulmonary fibrosis are driving the market growth of the global idiopathic pulmonary fibrosis treatment market. The aging population is increasingly utilizing healthcare resources, leading to a growing demand for specialized care, particularly for chronic diseases like idiopathic pulmonary fibrosis. Advancements in medical diagnostics and increased awareness may increase early and accurate diagnoses, leading to a higher demand for appropriate treatments. This recognition of idiopathic pulmonary fibrosis as a significant health concern may drive research and development efforts to discover and commercialize innovative treatment options.

Asia Pacific region is predicted to hold a significant market share

Asia Pacific region is having more market growth in idiopathic pulmonary fibrosis treatment. The rising number of lung patients and people suffering from Idiopathic Pulmonary Fibrosis in the Asia Pacific region is raising the market growth of idiopathic pulmonary Fibrosis treatment in Asia. The large investments made in the medication sector are also boosting market growth. The Asia Pacific region is experiencing a surge in awareness of idiopathic pulmonary fibrosis (IPF), leading to increased demand for treatments. The region's aging population, which is more common in older individuals, is also contributing to the disease's prevalence. Improvements in healthcare infrastructure and access to advanced medical treatments could improve diagnosis and treatment. Increased investment in research and development could lead to novel therapies and market share growth. Government initiatives, healthcare policies, and reimbursement programs could encourage the adoption of advanced treatments. Collaborations between pharmaceutical companies, research institutions, and healthcare providers could lead to the development and commercialization of effective IPF treatments. Patient advocacy groups can also play a role in raising awareness and influencing policies.

Key Developments:

  • January 2023- Lotus Pharmaceutical has received tentative approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Nintedanib Capsules, a generic version of Boehringer Ingelheim's OFEV(R). The company plans to launch the generic Nintedanib Capsules at the earliest available opportunity.
  • May 2022- Sandoz has announced the launch of its first generic pirfenidone in the US for treating idiopathic pulmonary fibrosis (IPF), a rare, progressive disease primarily affecting adults over 50. The AB-rated medication is the first fully substitutable equivalent to Genentech's Esbriet and is now available through specialty pharmacies with a $0 co-pay program for eligible patients. IPF is a progressive, rare disease with no cure, affecting approximately 140,000 Americans.

Segmentation

By Treatment Type

  • Drug class
  • Oxygen Therapy
  • Lung Transplant
  • Others

By Drug Type

  • Pirfenidone
  • Nintedanib

By Application

  • Hospital
  • Clinic

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • UK
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline
  • 1.8. Key Benefits to the stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. CXO Perspective

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE

  • 5.1. Introduction
  • 5.2. Drug class
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Oxygen Therapy
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Lung Transplant
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Others
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness

6. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET, BY DRUG TYPE

  • 6.1. Introduction
  • 6.2. Pirfenidone
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Nintedanib
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness

7. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET, BY APPLICATION

  • 7.1. Introduction
  • 7.2. Hospital
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Clinic
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness

8. GLOBAL IDIOPATHIC PULMONARY FIBROSIS TREATMENT MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Treatment Type
    • 8.2.2. By Drug Type
    • 8.2.3. By Application
    • 8.2.4. By Country
      • 8.2.4.1. United States
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Treatment Type
    • 8.3.2. By Drug Type
    • 8.3.3. By Application
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Treatment Type
    • 8.4.2. By Drug Type
    • 8.4.3. By Application
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. Germany
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. France
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Italy
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
      • 8.4.4.5. Spain
        • 8.4.4.5.1. Market Opportunities and Trends
        • 8.4.4.5.2. Growth Prospects
      • 8.4.4.6. Others
        • 8.4.4.6.1. Market Opportunities and Trends
        • 8.4.4.6.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Treatment Type
    • 8.5.2. By Drug Type
    • 8.5.3. By Application
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. UAE
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Others
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Treatment Type
    • 8.6.2. By Drug Type
    • 8.6.3. By Application
    • 8.6.4. By Country
      • 8.6.4.1. Japan
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. China
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. India
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. South Korea
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Taiwan
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Thailand
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Indonesia
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Others
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Boehringer Ingelheim GMBH
  • 10.2. Bristol-Myers Squibb Company
  • 10.3. Biogen
  • 10.4. Cipla
  • 10.5. Hoffman-La Roche AG
  • 10.6. Fibrogen, Inc.
  • 10.7. Galapagos NV
  • 10.8. Medicinova, Inc.
  • 10.9. Novartis AG
  • 10.10. Prometic Life sciences Inc.